92 related articles for article (PubMed ID: 1572758)
1. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay.
Weyhenmeyer R; Mascher H; Birkmayer J
Int J Clin Pharmacol Ther Toxicol; 1992 Apr; 30(4):134-8. PubMed ID: 1572758
[TBL] [Abstract][Full Text] [Related]
2. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application.
Wu JW; Lin LC; Hung SC; Chi CW; Tsai TH
J Pharm Biomed Anal; 2007 Nov; 45(4):635-41. PubMed ID: 17692492
[TBL] [Abstract][Full Text] [Related]
3. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection.
Rickling B; Hans B; Kramarczyk R; Krumbiegel G; Weyhenmeyer R
J Chromatogr B Biomed Appl; 1995 Aug; 670(2):267-77. PubMed ID: 8548017
[TBL] [Abstract][Full Text] [Related]
4. Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats.
Wu JW; Lin LC; Hung SC; Lin CH; Chi CW; Tsai TH
Drug Metab Dispos; 2008 Mar; 36(3):589-96. PubMed ID: 18048488
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
6. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers.
Han Y; Guo D; Chen Y; Tan ZR; Zhou HH
Xenobiotica; 2009 Sep; 39(9):694-9. PubMed ID: 19555315
[TBL] [Abstract][Full Text] [Related]
7. Multiple-dose pharmacokinetics of ofloxacin, a new broad-spectrum antimicrobial agent.
Dagrosa EE; Verho M; Malerczyk V; de Looze S; Hajdú P; Toyodera K
Clin Ther; 1986; 8(6):632-45. PubMed ID: 3466701
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic studies with silymarin in human serum and bile.
Lorenz D; Lücker PW; Mennicke WH; Wetzelsberger N
Methods Find Exp Clin Pharmacol; 1984 Oct; 6(10):655-61. PubMed ID: 6513680
[TBL] [Abstract][Full Text] [Related]
9. Herb-drug interaction of silymarin or silibinin on the pharmacokinetics of trazodone in rats.
Chang JC; Wu YT; Lee WC; Lin LC; Tsai TH
Chem Biol Interact; 2009 Dec; 182(2-3):227-32. PubMed ID: 19765569
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability of silibinin in healthy male volunteers.
Kim YC; Kim EJ; Lee ED; Kim JH; Jang SW; Kim YG; Kwon JW; Kim WB; Lee MG
Int J Clin Pharmacol Ther; 2003 Dec; 41(12):593-6. PubMed ID: 14692709
[TBL] [Abstract][Full Text] [Related]
11. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
Singh RP; Dhanalakshmi S; Tyagi AK; Chan DC; Agarwal C; Agarwal R
Cancer Res; 2002 Jun; 62(11):3063-9. PubMed ID: 12036915
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction.
Schandalik R; Perucca E
Drugs Exp Clin Res; 1994; 20(1):37-42. PubMed ID: 7924893
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of oral silibinin, a putative chemopreventive agent, in colorectal cancer patients: silibinin levels in plasma, colorectum, and liver and their pharmacodynamic consequences.
Hoh C; Boocock D; Marczylo T; Singh R; Berry DP; Dennison AR; Hemingway D; Miller A; West K; Euden S; Garcea G; Farmer PB; Steward WP; Gescher AJ
Clin Cancer Res; 2006 May; 12(9):2944-50. PubMed ID: 16675592
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.
Meyer MC; Straughn AB; Lo MW; Schary WL; Whitney CC
J Clin Psychiatry; 1984 Sep; 45(9 Pt 2):15-9. PubMed ID: 6469932
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.
Schrieber SJ; Wen Z; Vourvahis M; Smith PC; Fried MW; Kashuba AD; Hawke RL
Drug Metab Dispos; 2008 Sep; 36(9):1909-16. PubMed ID: 18566043
[TBL] [Abstract][Full Text] [Related]
17. Dose linearity and other pharmacokinetics of cefodizime after single-dose intravenous administration.
Dagrosa EE; Hajdú P; Malerczyk V; de Looze S; Seeger K; Grötsch H
Clin Ther; 1987; 10(1):18-31. PubMed ID: 3450392
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and safety of silibinin in horses.
Hackett ES; Mama KR; Twedt DC; Gustafson DL
Am J Vet Res; 2013 Oct; 74(10):1327-32. PubMed ID: 24066917
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
Tyagi A; Bhatia N; Condon MS; Bosland MC; Agarwal C; Agarwal R
Prostate; 2002 Nov; 53(3):211-7. PubMed ID: 12386921
[TBL] [Abstract][Full Text] [Related]
20. Effect of silibinin on the pharmacokinetics of pyrazinamide and pyrazinoic acid in rats.
Wu JW; Tsai TH
Drug Metab Dispos; 2007 Sep; 35(9):1603-10. PubMed ID: 17540707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
